CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT:

) ("CEL SCI" or the "Company") today announced that in June it has enrolled 25 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in just diagnosed, not yet treated patients with head and neck cancer. Total patient enrollment is now 488 as of June 30, 2015 in the world's largest Phase 3 study in head and neck cancer. A total of 880 patients are expected to be enrolled, through approximately 100 clinical centers in about 25 countries by the end of March 2016. About the Multikine Phase 3 Study The Multikine Phase 3 study is enrolling just diagnosed, not yet treated patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care ("SOC") vs. subjects who are treated with SOC only. Standard of Care for these patients consists of the surgical removal of the tumor and any locally involved lymph nodes, followed by radiotherapy or concurrent radiochemotherapy.